References
- Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004; 4:216 - 25; http://dx.doi.org/10.1038/nrc1296; PMID: 14993903
- Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004; 3:513 - 9; PMID: 15078995
- Levesque AA, Eastman A. p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor?. Carcinogenesis 2007; 28:13 - 20; http://dx.doi.org/10.1093/carcin/bgl214; PMID: 17088261
- Booth L, Cruickshanks N, Ridder T, Dai Y, Grant S, Dent P. PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. Cancer Biol Ther 2013; 14:458 - 65; http://dx.doi.org/10.4161/cbt.24424; PMID: 23917378
- Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, Kimura T, Kaneko N, Ohtani J, Yamanaka K, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009; 8:2992 - 3000; http://dx.doi.org/10.1158/1535-7163.MCT-09-0463; PMID: 19887545
- Leijen S, Schellens JH, Shapiro G, Pavlick R, Tibes T, Demuth J, Viscusi J, Cheng JD, Xu Y, Oza AM. A phase I pharmacological and pharmacodynamics study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol 2010; 28:15s
- Indovina P, Marcelli E, Di Marzo D, Casini N, Forte IM, Giorgi F, Alfano L, Pentimalli F, Giordano A. Abrogating G 2/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma. Cancer Biol Ther 2014; 15:380 - 8; http://dx.doi.org/10.4161/cbt.27623; PMID: 24365782
- Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, Imagaki K, Ohtani J, Sakai T, Yoshizumi T, et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010; 9:514 - 22; http://dx.doi.org/10.4161/cbt.9.7.11115; PMID: 20107315
- Krajewska M, Heijink AM, Bisselink YJ, Seinstra RI, Silljé HH, de Vries EG, van Vugt MA. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. Oncogene 2013; 32:3001 - 8; http://dx.doi.org/10.1038/onc.2012.296; PMID: 22797065
- Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, Toniatti C, Ashworth A, Turner NC. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov 2012; 2:524 - 39; http://dx.doi.org/10.1158/2159-8290.CD-11-0320; PMID: 22628408
- Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, Kimura T, Kaneko N, Ohtani J, Yamanaka K, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009; 8:2992 - 3000; http://dx.doi.org/10.1158/1535-7163.MCT-09-0463; PMID: 19887545